比美吉珠单抗在老年斑块型银屑病患者队列中的真实世界经验：一项24周的回顾性研究。 - Suppr

Suppr

超能文献

Real-World Experience of Bimekizumab in an Elderly Patients Cohort with Plaque-Type Psoriasis: A 24-Week Retrospective Study.

作者信息

Fratton Zeno, Maione Vincenzo, Bighetti Stefano, Bettolini Luca, Arisi Mariachiara, Stinco Giuseppe, Errichetti Enzo

机构信息

Department of Medicine, Institute of Dermatology, University of Udine, Udine, Italy.

Dermatology Department, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy.

出版信息

Clin Cosmet Investig Dermatol. 2024 Sep 30;17:2177-2181. doi: 10.2147/CCID.S487869. eCollection 2024.

DOI:10.2147/CCID.S487869

PMID:39372261

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11451462/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2fe9/11451462/a77ebf3b29ac/CCID-17-2177-g0001.jpg

相似文献

Real-World Experience of Bimekizumab in an Elderly Patients Cohort with Plaque-Type Psoriasis: A 24-Week Retrospective Study.

Clin Cosmet Investig Dermatol. 2024 Sep 30;17:2177-2181. doi: 10.2147/CCID.S487869. eCollection 2024.

Efficacy and Safety of bimekizumab in elderly patients: real-world multicenter retrospective study - IL PSO (Italian Landscape Psoriasis).

J Dermatolog Treat. 2024 Dec;35(1):2393376. doi: 10.1080/09546634.2024.2393376. Epub 2024 Aug 20.

Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis).

Front Med (Lausanne). 2023 Aug 8;10:1243843. doi: 10.3389/fmed.2023.1243843. eCollection 2023.

Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 52-week multicenter retrospective study.

J Am Acad Dermatol. 2024 Nov;91(5):936-939. doi: 10.1016/j.jaad.2024.05.085. Epub 2024 Jun 15.

Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 16-week multicenter retrospective study.

J Am Acad Dermatol. 2024 Aug;91(2):359-361. doi: 10.1016/j.jaad.2024.04.027. Epub 2024 Apr 20.

Bimekizumab for the Treatment of Plaque Psoriasis with Involvement of Genitalia: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis).

Dermatol Pract Concept. 2024 Apr 1;14(2):e2024052. doi: 10.5826/dpc.1402a52.

Effectiveness of bimekizumab for genital, nail, and scalp lesions with psoriasis: A 24-week real-world study.

J Dermatol. 2024 Dec;51(12):1658-1664. doi: 10.1111/1346-8138.17427. Epub 2024 Aug 12.

Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective review.

J Am Acad Dermatol. 2024 Dec;91(6):1265-1267. doi: 10.1016/j.jaad.2024.07.1515. Epub 2024 Aug 23.

Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.

Lancet. 2021 Feb 6;397(10273):475-486. doi: 10.1016/S0140-6736(21)00126-4.

Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.

Lancet. 2021 Feb 6;397(10273):487-498. doi: 10.1016/S0140-6736(21)00125-2.

引用本文的文献

Real-World Experience of Bimekizumab in a Cohort of 109 Patients Over 48 Weeks and Identification of Predictive Factors for an Early Super Response and Risk of Adverse Events.

Psoriasis (Auckl). 2025 Apr 11;15:145-158. doi: 10.2147/PTT.S514249. eCollection 2025.

本文引用的文献

Effectiveness of Ixekizumab in Elderly Patients for the Treatment of Moderate-to-Severe Psoriasis: Results From a Multicenter, Retrospective Real-Life Study in the Lazio Region.

Dermatol Pract Concept. 2024 Jul 1;14(3):e2024166. doi: 10.5826/dpc.1403a166.

Bimekizumab in psoriasis: a monocentric study evaluating short- and mid-term effectiveness and safety profile in a real-world setting.

Arch Dermatol Res. 2024 Apr 25;316(5):133. doi: 10.1007/s00403-024-02868-7.

Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 16-week multicenter retrospective study.

J Am Acad Dermatol. 2024 Aug;91(2):359-361. doi: 10.1016/j.jaad.2024.04.027. Epub 2024 Apr 20.

Real-world effectiveness and safety of bimekizumab in Japanese patients with psoriasis: A single-center retrospective study.

J Dermatol. 2024 May;51(5):649-658. doi: 10.1111/1346-8138.17186. Epub 2024 Mar 14.

Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER - study).

J Dermatolog Treat. 2024 Dec;35(1):2319304. doi: 10.1080/09546634.2024.2319304. Epub 2024 Feb 27.

Aging Impact in Response to Different Classes of Biological Treatment in Psoriatic Patients: A Real-Life Observational Study.

J Clin Med. 2023 Nov 21;12(23):7215. doi: 10.3390/jcm12237215.

Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials.

Br J Dermatol. 2024 Mar 15;190(4):477-485. doi: 10.1093/bjd/ljad429.

Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis).

Front Med (Lausanne). 2023 Aug 8;10:1243843. doi: 10.3389/fmed.2023.1243843. eCollection 2023.

Efficacy and Safety of Secukinumab in Elderly Patients with Moderate to Severe Plaque-Type Psoriasis: Post-Hoc Analysis of the SUPREME Study.

Clin Cosmet Investig Dermatol. 2023 Apr 1;16:847-852. doi: 10.2147/CCID.S400520. eCollection 2023.

The dark side of Tregs during aging.

Front Immunol. 2022 Aug 9;13:940705. doi: 10.3389/fimmu.2022.940705. eCollection 2022.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Real-World Experience of Bimekizumab in an Elderly Patients Cohort with Plaque-Type Psoriasis: A 24-Week Retrospective Study.

作者信息

Fratton Zeno, Maione Vincenzo, Bighetti Stefano, Bettolini Luca, Arisi Mariachiara, Stinco Giuseppe, Errichetti Enzo

机构信息

Department of Medicine, Institute of Dermatology, University of Udine, Udine, Italy.

Dermatology Department, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy.

出版信息

Clin Cosmet Investig Dermatol. 2024 Sep 30;17:2177-2181. doi: 10.2147/CCID.S487869. eCollection 2024.

DOI:10.2147/CCID.S487869

PMID:39372261

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11451462/

Abstract

摘要

相似文献

Real-World Experience of Bimekizumab in an Elderly Patients Cohort with Plaque-Type Psoriasis: A 24-Week Retrospective Study.

Clin Cosmet Investig Dermatol. 2024 Sep 30;17:2177-2181. doi: 10.2147/CCID.S487869. eCollection 2024.

Efficacy and Safety of bimekizumab in elderly patients: real-world multicenter retrospective study - IL PSO (Italian Landscape Psoriasis).

J Dermatolog Treat. 2024 Dec;35(1):2393376. doi: 10.1080/09546634.2024.2393376. Epub 2024 Aug 20.

Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis).

Front Med (Lausanne). 2023 Aug 8;10:1243843. doi: 10.3389/fmed.2023.1243843. eCollection 2023.

Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 52-week multicenter retrospective study.

J Am Acad Dermatol. 2024 Nov;91(5):936-939. doi: 10.1016/j.jaad.2024.05.085. Epub 2024 Jun 15.

Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 16-week multicenter retrospective study.

J Am Acad Dermatol. 2024 Aug;91(2):359-361. doi: 10.1016/j.jaad.2024.04.027. Epub 2024 Apr 20.

Bimekizumab for the Treatment of Plaque Psoriasis with Involvement of Genitalia: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis).

Dermatol Pract Concept. 2024 Apr 1;14(2):e2024052. doi: 10.5826/dpc.1402a52.

Effectiveness of bimekizumab for genital, nail, and scalp lesions with psoriasis: A 24-week real-world study.

J Dermatol. 2024 Dec;51(12):1658-1664. doi: 10.1111/1346-8138.17427. Epub 2024 Aug 12.

Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective review.

J Am Acad Dermatol. 2024 Dec;91(6):1265-1267. doi: 10.1016/j.jaad.2024.07.1515. Epub 2024 Aug 23.

Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.

Lancet. 2021 Feb 6;397(10273):475-486. doi: 10.1016/S0140-6736(21)00126-4.

Lancet. 2021 Feb 6;397(10273):487-498. doi: 10.1016/S0140-6736(21)00125-2.

引用本文的文献

Real-World Experience of Bimekizumab in a Cohort of 109 Patients Over 48 Weeks and Identification of Predictive Factors for an Early Super Response and Risk of Adverse Events.

Psoriasis (Auckl). 2025 Apr 11;15:145-158. doi: 10.2147/PTT.S514249. eCollection 2025.

本文引用的文献

Effectiveness of Ixekizumab in Elderly Patients for the Treatment of Moderate-to-Severe Psoriasis: Results From a Multicenter, Retrospective Real-Life Study in the Lazio Region.

Dermatol Pract Concept. 2024 Jul 1;14(3):e2024166. doi: 10.5826/dpc.1403a166.

Bimekizumab in psoriasis: a monocentric study evaluating short- and mid-term effectiveness and safety profile in a real-world setting.

Arch Dermatol Res. 2024 Apr 25;316(5):133. doi: 10.1007/s00403-024-02868-7.

Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 16-week multicenter retrospective study.

J Am Acad Dermatol. 2024 Aug;91(2):359-361. doi: 10.1016/j.jaad.2024.04.027. Epub 2024 Apr 20.

Real-world effectiveness and safety of bimekizumab in Japanese patients with psoriasis: A single-center retrospective study.

J Dermatol. 2024 May;51(5):649-658. doi: 10.1111/1346-8138.17186. Epub 2024 Mar 14.

Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER - study).

J Dermatolog Treat. 2024 Dec;35(1):2319304. doi: 10.1080/09546634.2024.2319304. Epub 2024 Feb 27.

Aging Impact in Response to Different Classes of Biological Treatment in Psoriatic Patients: A Real-Life Observational Study.

J Clin Med. 2023 Nov 21;12(23):7215. doi: 10.3390/jcm12237215.

Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials.

Br J Dermatol. 2024 Mar 15;190(4):477-485. doi: 10.1093/bjd/ljad429.

Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis).

Front Med (Lausanne). 2023 Aug 8;10:1243843. doi: 10.3389/fmed.2023.1243843. eCollection 2023.

Efficacy and Safety of Secukinumab in Elderly Patients with Moderate to Severe Plaque-Type Psoriasis: Post-Hoc Analysis of the SUPREME Study.

Clin Cosmet Investig Dermatol. 2023 Apr 1;16:847-852. doi: 10.2147/CCID.S400520. eCollection 2023.

The dark side of Tregs during aging.

Front Immunol. 2022 Aug 9;13:940705. doi: 10.3389/fimmu.2022.940705. eCollection 2022.